Scheinberg DA - Search Results

1

Therapeutic targeting of PRAME with mTCRCAR T cells in acute myeloid leukemia.

Kirkey DC, Loeb AM, Castro S, McKay CN, Perkins L, Pardo L, Leonti AR, Tang TT, Loken MR, Brodersen LE, Loeb KR, Scheinberg DA, Le Q, Meshinchi S. Kirkey DC, et al. Among authors: scheinberg da. Blood Adv. 2023 Apr 11;7(7):1178-1189. doi: 10.1182/bloodadvances.2022008304. Blood Adv. 2023. PMID: 35984639 Free PMC article.

2

Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid "resistance" in patients with acute promyelocytic leukemia.

Muindi J, Frankel SR, Miller WH Jr, Jakubowski A, Scheinberg DA, Young CW, Dmitrovsky E, Warrell RP Jr. Muindi J, et al. Among authors: scheinberg da. Blood. 1992 Jan 15;79(2):299-303. Blood. 1992. PMID: 1309668 Free article.

3

Autologous bone marrow transplantation in acute myelogenous leukemia: in vitro treatment with myeloid-specific monoclonal antibodies and drugs in combination.

Lemoli RM, Gasparetto C, Scheinberg DA, Moore MA, Clarkson BD, Gulati SC. Lemoli RM, et al. Among authors: scheinberg da. Blood. 1991 Apr 15;77(8):1829-36. Blood. 1991. PMID: 2015406 Free article. Clinical Trial.

4

Human immunodeficiency virus infection in patients with leukemia.

Minamoto GY, Scheinberg DA, Dietz K, Gold JW, Chein N, Gee T, Reich LM, Hoffer J, Mayer K, Armstrong D, et al. Minamoto GY, et al. Among authors: scheinberg da. Blood. 1988 Apr;71(4):1147-9. Blood. 1988. PMID: 3355892 Free article.

5

Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules.

Bocchia M, Wentworth PA, Southwood S, Sidney J, McGraw K, Scheinberg DA, Sette A. Bocchia M, et al. Among authors: scheinberg da. Blood. 1995 May 15;85(10):2680-4. Blood. 1995. PMID: 7742526 Free article.

6

Specific human cellular immunity to bcr-abl oncogene-derived peptides.

Bocchia M, Korontsvit T, Xu Q, Mackinnon S, Yang SY, Sette A, Scheinberg DA. Bocchia M, et al. Among authors: scheinberg da. Blood. 1996 May 1;87(9):3587-92. Blood. 1996. PMID: 8611681 Free article.

7

Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses.

Pinilla-Ibarz J, Cathcart K, Korontsvit T, Soignet S, Bocchia M, Caggiano J, Lai L, Jimenez J, Kolitz J, Scheinberg DA. Pinilla-Ibarz J, et al. Among authors: scheinberg da. Blood. 2000 Mar 1;95(5):1781-7. Blood. 2000. PMID: 10688838 Free article. Clinical Trial.

8

Targeted alpha particle immunotherapy for myeloid leukemia.

Jurcic JG, Larson SM, Sgouros G, McDevitt MR, Finn RD, Divgi CR, Ballangrud AM, Hamacher KA, Ma D, Humm JL, Brechbiel MW, Molinet R, Scheinberg DA. Jurcic JG, et al. Among authors: scheinberg da. Blood. 2002 Aug 15;100(4):1233-9. Blood. 2002. PMID: 12149203 Free article. Clinical Trial.

9

A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia.

Cathcart K, Pinilla-Ibarz J, Korontsvit T, Schwartz J, Zakhaleva V, Papadopoulos EB, Scheinberg DA. Cathcart K, et al. Among authors: scheinberg da. Blood. 2004 Feb 1;103(3):1037-42. doi: 10.1182/blood-2003-03-0954. Epub 2003 Sep 22. Blood. 2004. PMID: 14504104 Free article. Clinical Trial.

10

Remodeling specific immunity by use of MHC tetramers: demonstration in a graft-versus-host disease model.

Kappel BJ, Pinilla-Ibarz J, Kochman AA, Eng JM, Hubbard VM, Leiner I, Pamer EG, Heller G, van den Brink MR, Scheinberg DA. Kappel BJ, et al. Among authors: scheinberg da. Blood. 2006 Mar 1;107(5):2045-51. doi: 10.1182/blood-2005-07-2828. Epub 2005 Nov 3. Blood. 2006. PMID: 16269613 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

299 results

Search Page

Filters